0000000001102992

AUTHOR

Gina Ferrazzano

showing 2 related works from this author

Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study

2020

Background\ud Functional motor disorders (FMDs) are abnormal movements that are significantly altered by distractive maneuvers and are incongruent with movement disorders seen in typical neurological diseases.\ud \ud Objective\ud The objectives of this article are to (1) describe the clinical manifestations of FMDs, including nonmotor symptoms and occurrence of other functional neurological disorders (FND); and (2) to report the frequency of isolated and combined FMDs and their relationship with demographic and clinical variables.\ud \ud Methods\ud For this multicenter, observational study, we enrolled consecutive outpatients with a definite diagnosis of FMDs attending 25 tertiary movement …

0301 basic medicineWeaknessPediatricsmedicine.medical_specialtyMovement disordersfunctional neurological disordersdiagnosisPopulationfunctional weakneDisease030105 genetics & heredityfunctional weakness03 medical and health sciences0302 clinical medicinefunctional neurological disordermedicineeducationResearch Articleseducation.field_of_studyfunctional neurological disorders; functional dystonia; functional tremor; functional weakness; diagnosisbusiness.industryfunctional neurological disorders functional dystonia functional tremor functional weakness diagnosisFunctional weaknessfunctional dystoniatremorNeurologyMulticenter studyAnxietyfunctional tremorSettore MED/26 - NeurologiaObservational studydystoniaNeurology (clinical)medicine.symptombusinessfunctional neurological disorders functional dystonia functional tremor functional weakness diagnosis.030217 neurology & neurosurgery
researchProduct

Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

2020

The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed the therapeutic landscape and algorithms of RRMS treatment (1). In Europe, dimethyl fumarate (DMF) and teriflunomide (TRF) are approved as first-line agents and are often used as the initial therapeutic choice (2, 3). Pivotal trials showed the efficacy of both DMTs on controlling clinical relapses, disability accrual and magnetic resonance imaging (MRI) activity (4-8). Both DMTs had overall good tolerability. There have been no head-to-head randomized trials to compare these two DMTs; however, several real-world evidence (RWE) studies have compared DMF and TRF and provided u…

Cox models relapsing-remitting mul tiple sclerosis dimethyl fumarate teriflunomide
researchProduct